Drug profile · INN
lebrikizumab-lbkz
EBGLYSS
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
lebrikizumab-lbkz (EBGLYSS) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN lebrikizumab-lbkz
Brand EBGLYSS
Route INJECTION
Formulation INJECTABLE
Frequently asked questions
What is lebrikizumab-lbkz?
lebrikizumab-lbkz (EBGLYSS) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for lebrikizumab-lbkz?
EBGLYSS is a marketed brand name for lebrikizumab-lbkz. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lebrikizumab-lbkz?
lebrikizumab-lbkz has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.